

Robert G Gish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/625151/publications.pdf>

Version: 2024-02-01

318
papers

15,351
citations

14655

66
h-index

20358

116
g-index

328
all docs

328
docs citations

328
times ranked

14610
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	12.1	25
2	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 374-382.	1.4	8
3	Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. <i>Hepatology</i> , 2022, 75, 1062-1063.	7.3	2
4	The <sc>NAFLDâ€MAFLD</sc> debate: Is there a Consensusâ€onâ€Consensus methodology?. <i>Liver International</i> , 2022, 42, 742-748.	3.9	15
5	Letter to the editor: Beneath the surface of the pandemic: Persons with alcoholâ€associated liver disease need our attention. <i>Hepatology</i> , 2022, 76, E7-E8.	7.3	0
6	A multiâ€analyte cellâ€free DNAâ€based blood test for early detection of hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1753-1763.	4.3	41
7	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.2	2
8	Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review. <i>Cells</i> , 2022, 11, 1998.	4.1	2
9	Global trends and the impact of chronic hepatitis B and C on <sc>disabilityâ€adjusted</sc> life years. <i>Liver International</i> , 2022, 42, 2145-2153.	3.9	7
10	Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b. <i>Hepatology Research</i> , 2021, 51, 156-165.	3.4	3
11	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreignâ€Born Persons Living in the United States. <i>Hepatology</i> , 2021, 74, 607-626.	7.3	64
12	Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 1267-1279.	1.6	8
13	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. <i>American Journal of Medicine</i> , 2021, 134, 882-892.	1.5	3
14	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	8.1	60
15	MAFLD and Cardiovascular Events: What Does the Evidence Show?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2025-2028.	4.4	11
16	Hepatitis C Vaccination: Where We Are and Where We Need to Be. <i>Pathogens</i> , 2021, 10, 1619.	2.8	4
17	RNA Interference Therapy With ARCâ€520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84
18	We Are All Africans: A Highly Personal Migratory View of the History of Hepatitis B. <i>Clinical Liver Disease</i> , 2020, 16, 24-33.	2.1	1

#	ARTICLE	IF	CITATIONS
19	Tu1185 OLDER AGE AND PRESENCE OF ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS IS ASSOCIATED WITH SIGNIFICANTLY GREATER HEALTHCARE RESOURCE UTILIZATION OF RADIOLOGY SERVICES. <i>Gastroenterology</i> , 2020, 158, S-1010.	1.3	0
20	Mo1459 SEX-SPECIFIC AND RACE/ETHNICITY-SPECIFIC DIFFERENCES IN PERFORMANCE CHARACTERISTICS OF NON-INVASIVE SEROLOGICAL SCORING SYSTEMS TO PREDICT ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS. <i>Gastroenterology</i> , 2020, 158, S-1411.	1.3	0
21	Point of Care Diagnostic Testing for Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2020, 19, 245-253.	0.9	2
22	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1429-1438.	0.4	92
23	Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. <i>Current Therapeutic Research</i> , 2020, 93, 100594.	1.2	1
24	Geographic regions with high prevalence of nonalcoholic steatohepatitis-related hepatic fibrosis are also observed to demonstrate high prevalence of metabolic disease risk factors and low consumption of fruits and vegetables. <i>Clinical Nutrition Experimental</i> , 2020, 30, 15-26.	2.0	1
25	Hepatitis B Core Antibody: Role in Clinical Practice in 2020. <i>Current Hepatology Reports</i> , 2020, 19, 254-265.	0.9	14
26	Normal alkaline phosphatase levels are dependent on race/ethnicity: NationalGEP Health and Nutrition Examination Survey data. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000502.	2.7	7
27	1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing. <i>Open Forum Infectious Diseases</i> , 2020, 7, S562-S562.	0.9	0
28	Editorial: tenofovir alafenamide fumarateâ€”a new silver bullet to prevent motherâ€™toâ€™child transmission of hepatitis B virus. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1744-1745.	3.7	1
29	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0220612.	2.5	17
30	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 511-519.	2.1	2
31	Global Perspective on Hepatitis B Virus Infections in the Era of Effective Vaccines. <i>Clinics in Liver Disease</i> , 2019, 23, 383-399.	2.1	23
32	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 487-492.	2.1	5
33	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 493-509.	2.1	4
34	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 521-534.	2.1	2
35	PS-052-End of study results from LIMIT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019, 70, e32.	3.7	44
36	LBP-38-Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e160.	3.7	0

#	ARTICLE	IF	CITATIONS
37	SAT-494-Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database. <i>Journal of Hepatology</i> , 2019, 70, e851-e852.	3.7	0
38	Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. <i>BMJ Open</i> , 2019, 9, e028248.	1.9	27
39	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. <i>Journal of Hepatology</i> , 2019, 70, e51-e52.	3.7	27
40	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000256.	2.7	11
41	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e392-e399.	2.2	10
42	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
43	Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States. <i>Journal of Viral Hepatitis</i> , 2019, 26, 350-361.	2.0	16
44	Title is missing!. , 2019, 14, e0220612.		0
45	Title is missing!. , 2019, 14, e0220612.		0
46	Title is missing!. , 2019, 14, e0220612.		0
47	Title is missing!. , 2019, 14, e0220612.		0
48	Identification of recombinant strains in <sc>HCV</sc> genotype 1 and 3: Is it needed?. <i>Liver International</i> , 2018, 38, 958-958.	3.9	1
49	Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 146-148.	4.4	1
50	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
51	Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. <i>Liver International</i> , 2018, 38, 451-457.	3.9	13
52	Sa1516 - Widening Disparities in Model for End Stage Liver Disease Scores at Time of Liver Transplant Waitlist Registration and at Time of Liver Transplantation: an Analysis of the 2005-2016 United Network for Organ Sharing Registry Data. <i>Gastroenterology</i> , 2018, 154, S-1139-S-1140.	1.3	0
53	Global HBV burden: guesstimates and facts. <i>Hepatology International</i> , 2018, 12, 315-329.	4.2	68
54	Su1472 - African Americans and Patients with Alcoholic Liver Disease have Significantly Higher Model for end Stage Liver Disease (MELD) Scores at Time of Waitlist Registration and at Time of Liver Transplantation. <i>Gastroenterology</i> , 2018, 154, S-531.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. <i>Clinical Liver Disease</i> , 2018, 12, 5-11.	2.1	11
56	Epidemiology and Natural History of Chronic Hepatitis B Virus Infection. , 2018, , 63-89.		7
57	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	8.1	45
58	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 707-716.	3.1	31
59	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017, 66, S27.	3.7	18
60	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
61	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000158.	2.7	3
62	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population. <i>Journal of Hepatology</i> , 2017, 66, S265.	3.7	7
63	Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia. <i>Journal of Hepatology</i> , 2017, 66, S302-S303.	3.7	0
64	Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network. <i>Journal of Hepatology</i> , 2017, 66, S257-S258.	3.7	2
65	Markov modeling in hepatitis B screening and linkage to care. <i>Theoretical Biology and Medical Modelling</i> , 2017, 14, 11.	2.1	11
66	Drugs in Development for Hepatitis B. <i>Drugs</i> , 2017, 77, 1263-1280.	10.9	29
67	Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 350-362.	1.6	69
68	Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 17-21.	2.0	15
69	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1089-1097.	2.0	20
70	HBV/HCV Coinfection and Possible Reactivation of HBV Following DAA Use. <i>Gastroenterology and Hepatology</i> , 2017, 13, 292-295.	0.1	2
71	Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 2512-2523.	4.1	86
72	Future Therapy for Hepatitis B Virus: Role of Immunomodulators. <i>Current Hepatology Reports</i> , 2016, 15, 237-244.	0.9	22

#	ARTICLE	IF	CITATIONS
73	Tu1653 Bringing HCV Treatment to the Community: Preliminary Clinical Outcomes of an FQHC-based HCV Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1157.	1.3	0
74	Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 563-580.	2.1	47
75	Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. <i>Hepatology International</i> , 2016, 10, 624-631.	4.2	11
76	Differential Reductions in Viral Antigens Expressed from CCCDNAs Integrated DNA in Treatment Na ⁺ ve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016, 64, S390-S391.	3.7	23
77	Low Sustained Virologic Response (SVR) Rates in Genotype (GT) 2 and 3 Patients with Quantifiable Hepatitis C Virus (HCV) at Week 4 of Treatment with Sofosbuvir (SOF) Containing Regimens. <i>Journal of Hepatology</i> , 2016, 64, S786.	3.7	1
78	Sofosbuvir/Ledipasvir without Ribavirin in the Treatment of Asians with Chronic Hepatitis C Virus Genotype 6 in the United States: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016, 64, S815-S816.	3.7	4
79	Primary Care Physicians Utilizing the Echo Model Equally Effective as Subspecialists Treating HCV using Direct-Acting Antivirals-Only Regimens: Results of the Echo Model. <i>Journal of Hepatology</i> , 2016, 64, S818-S819.	3.7	2
80	Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance. <i>Journal of Hepatology</i> , 2016, 64, S398.	3.7	11
81	The Prevalence of Non-Alcoholic Steatohepatitis among Diabetic Patients Followed by Primary Care and Endocrinology. <i>Journal of Hepatology</i> , 2016, 64, S486.	3.7	1
82	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 887-897.	3.2	13
83	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
84	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	2.4	22
85	High Rates of Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy: Community-Based Real World Outcomes. <i>Journal of Hepatology</i> , 2016, 64, S601.	3.7	0
86	Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAi) Therapy Based on HBsAg Epitope Profile Analysis. <i>Journal of Hepatology</i> , 2016, 64, S602.	3.7	4
87	424 Development of a Community-Based Testing, Linkage, and Hepatitis C Treatment Program. <i>Gastroenterology</i> , 2016, 150, S1033.	1.3	0
88	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 41-56.	4.4	4
89	Hepatitis C virus as a systemic disease: reaching beyond the liver. <i>Hepatology International</i> , 2016, 10, 415-423.	4.2	131
90	Chronic hepatitis B virus in the Philippines. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 945-952.	2.8	7

#	ARTICLE	IF	CITATIONS
91	Views of US Voters on Compensating Living Kidney Donors. JAMA Surgery, 2016, 151, 710.	4.3	21
92	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. Journal of Hepatology, 2016, 64, 326-332.	3.7	21
93	Surgical Treatment of Hepatocellular Carcinoma: Resection Versus Transplantation. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 73-84.	0.0	2
94	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterology and Hepatology, 2016, 12, 293-9.	0.1	13
95	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. Gastroenterology and Hepatology, 2016, 12, 679-689.	0.1	1
96	Medical interventions associated with HBV reactivation: Common and less common. Clinical Liver Disease, 2015, 5, 32-34.	2.1	4
97	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology, 2015, 62, 1339-1341.	7.3	33
98	United Network for Organ Sharing regional variations in appeal denial rates with non-Standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board. Clinical Transplantation, 2015, 29, 513-522.	1.6	14
99	Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patients. BMJ Open Gastroenterology, 2015, 2, e000030.	2.7	2
100	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". Hepatology, 2015, 62, 1620-1622.	7.3	125
101	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transplantation, 2015, 21, 873-880.	2.4	31
102	Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterology, 2015, 2, e000032.	2.7	28
103	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World Journal of Gastroenterology, 2015, 21, 4644-4651.	3.3	25
104	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". Clinics and Research in Hepatology and Gastroenterology, 2015, 39, e57-e59.	1.5	36
105	High rate of core promoter and precore mutations in patients with chronic hepatitis B. Hepatology International, 2015, 9, 209-217.	4.2	8
106	Elevated Alpha-Fetoprotein. Clinics in Liver Disease, 2015, 19, 309-323.	2.1	118
107	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Research, 2015, 121, 97-108.	4.1	116
108	Spontaneous Regression of HCC: A Case Report. Clinical Gastroenterology and Hepatology, 2015, 13, e112.	4.4	0

#	ARTICLE	IF	CITATIONS
109	Unilateral Sensori-Neural Hearing Loss Induced by Pegylated Interferon Î±2a: A Case Report. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e113.	4.4	0
110	LP55 : Response guided therapy is not dead: Low Sustained Virologic Response (SVR) rates in patients who have detectable Hepatitis C Virus (HCV) at week 4 of treatment with SOFOSBUVIR (SOF) containing regimens. <i>Journal of Hepatology</i> , 2015, 62, S290.	3.7	1
111	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015, 121, 47-58.	4.1	216
112	Sa1854 Birth Cohort-Specific Disparities in Hepatocellular Carcinoma (HCC) Outcomes: Individuals Born Between 1945 to 1965 Have Higher Rates of HCC With Milan Criteria, Higher Rates of HCC Treatment, and Significantly Higher Long-Term Survival. <i>Gastroenterology</i> , 2015, 148, S-1025.	1.3	0
113	953 Race/Ethnicity-Specific Disparities in Cancer Incidence, Burden of Disease, and Overall Survival Among Patients With Hepatocellular Carcinoma in the U.S.: An Updated Analysis of the Surveillance, Epidemiology, and End Results Cancer Registry. <i>Gastroenterology</i> , 2015, 148, S-185.	1.3	0
114	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.4	30
115	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.9	15
116	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015, 149, 1627-1629.	1.3	96
117	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	4.4	16
118	Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia. <i>JIMD Reports</i> , 2015, 25, 87-94.	1.5	27
119	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	3.7	85
120	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	12.1	28
121	American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. <i>Gastroenterology</i> , 2015, 148, 221-244.e3.	1.3	432
122	Portal Vein Thrombosis. <i>Clinics in Liver Disease</i> , 2015, 19, 199-221.	2.1	41
123	The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization. <i>PLoS ONE</i> , 2015, 10, e0140870.	2.5	24
124	A Case of IgG4-Related Disease: A Unique Presentation of a Rare Entity. <i>American Journal of Gastroenterology</i> , 2015, 110, S109-S110.	0.4	0
125	Recurrent Post-partum Jaundice: Rare Genetic Disorder With Novel Genetic Mutations Identified. <i>American Journal of Gastroenterology</i> , 2015, 110, S397.	0.4	0
126	Hepatocellular Carcinoma: Current Questions and Future Directions. <i>Gastroenterology and Hepatology</i> , 2015, 11, 182-5.	0.1	2

#	ARTICLE	IF	CITATIONS
127	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. Digestive Diseases and Sciences, 2014, 59, 3073-3077.	2.3	25
128	Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transplantation, 2014, 20, n/a-n/a.	2.4	46
129	Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology, 2014, 48, 773-783.	2.2	11
130	A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. Journal of Viral Hepatitis, 2014, 21, 905-908.	2.0	29
131	Hepatitis Delta: Epidemiology, Diagnosis and Management 36 Years After Discovery. Current Gastroenterology Reports, 2014, 16, 365.	2.5	94
132	Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 511-520.	2.3	20
133	Immunosuppression in Patients with Chronic Hepatitis B. Current Hepatology Reports, 2014, 13, 235-244.	0.9	41
134	Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6413-6418.	7.1	224
135	Mo1047 HCC Surveillance: An Inquiry Into Current Practices in the United States. Gastroenterology, 2014, 146, S-995.	1.3	0
136	Hepatitis D Virus: A Call to Screening. Gastroenterology and Hepatology, 2014, 10, 647-86.	0.1	2
137	Chronic hepatitis B: What should be the goal for new therapies?. Antiviral Research, 2013, 98, 27-34.	4.1	112
138	One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. Journal of Virological Methods, 2013, 193, 531-535.	2.1	32
139	Cellular mechanics of germ band retraction in Drosophila. Developmental Biology, 2013, 384, 205-213.	2.0	23
140	759 IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAIVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology, 2013, 58, S308-S309.	3.7	3
141	516 Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naive HBeAg Positive Chronic Hepatitis B Patients. Gastroenterology, 2013, 144, S-950.	1.3	0
142	Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology, 2013, 57, 881-889.	7.3	195
143	Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1521-1525.	2.8	95
144	Society of interventional radiology critique and commentary on the cochrane report on transarterial chemoembolization. Hepatology, 2013, 57, 1675-1676.	7.3	9

#	ARTICLE	IF	CITATIONS
145	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naïve patients treated with entecavir. <i>Antiviral Therapy</i> , 2013, 18, 691-698.	1.0	18
146	Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. <i>Translational Cancer Research</i> , 2013, 2, 460-471.	1.0	9
147	Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterology and Hepatology</i> , 2013, 9, 219-27.	0.1	21
148	Delta virus infection: epidemiology and initiatives to intercept it. <i>Gastroenterology and Hepatology</i> , 2013, 9, 589-91.	0.1	0
149	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013, 9, 1-24.	0.1	5
150	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11 Suppl 5, 1-22; quiz 2 p following p22.	0.3	1
151	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	3.0	57
152	Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. <i>Cancer Biomarkers</i> , 2012, 11, 161-171.	1.7	49
153	The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 155-161.	2.2	61
154	Chronic HBV infection outside treatment guidelines: is treatment needed?. <i>Antiviral Therapy</i> , 2012, 18, 229-235.	1.0	17
155	Selection of chronic hepatitis B therapy with high barrier to resistance. <i>Lancet Infectious Diseases</i> , 2012, 12, 341-353.	9.1	127
156	469 Decline in Hepatitis B Surface Antigen Levels With Entecavir Treatment in HBeAg-Positive Nucleoside Naïve Chronic Hepatitis B Patients-Results From Phase III Study ETV-022. <i>Gastroenterology</i> , 2012, 142, S-917.	1.3	0
157	Su2034 Inhibition of Hec-1 as a Novel Approach to the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, S-978.	1.3	0
158	Chronic Hepatitis B Infection. <i>Clinics in Liver Disease</i> , 2012, 16, 347-369.	2.1	54
159	Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 941-946.	4.4	81
160	Liver disease in Viet Nam: Screening, surveillance, management and education: A 5-year plan and call to action. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 238-247.	2.8	28
161	HCV In At Risk Populations: Who Can be Treated and How?. <i>Current Hepatitis Reports</i> , 2012, 11, 1-9.	0.3	0
162	Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. <i>World Journal of Gastroenterology</i> , 2012, 18, 498.	3.3	52

#	ARTICLE	IF	CITATIONS
163	Acute liver failure in adults: an evidence-based management protocol for clinicians. <i>Gastroenterology and Hepatology</i> , 2012, 8, 161-212.	0.1	9
164	Hepatocellular Carcinoma: Locoregional and Targeted Therapies. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 599-610.	2.2	7
165	The NS5A Replication Complex Inhibitors: Difference Makers?. <i>Clinics in Liver Disease</i> , 2011, 15, 627-639.	2.1	28
166	Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician. <i>Clinics in Liver Disease</i> , 2011, 15, 307-321.	2.1	16
167	A Clinical Assessment of Wilson Disease in Patients With Concurrent Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 267-273.	2.2	16
168	Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 733-737.	2.2	5
169	RNA Interference and Its Potential Applications to Chronic HBV Treatment: Results of a Phase I Safety and Tolerability Study. <i>Antiviral Therapy</i> , 2011, 16, 547-554.	1.0	23
170	Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. <i>Clinical Transplantation</i> , 2011, 25, E152-62.	1.6	13
171	Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. <i>Journal of Viral Hepatitis</i> , 2011, 18, e40-51.	2.0	19
172	Is chronic hepatitis B being undertreated in the United States?. <i>Journal of Viral Hepatitis</i> , 2011, 18, 377-383.	2.0	153
173	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. <i>Digestive Diseases and Sciences</i> , 2011, 56, 578-585.	2.3	66
174	Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. <i>AIDS Research and Therapy</i> , 2011, 8, 29.	1.7	4
175	Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1222-1229.	2.5	36
176	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, .	1.8	0
177	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2011, 1, 45.	1.8	0
178	Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*. <i>Journal of Viral Hepatitis</i> , 2010, 17, 16-22.	2.0	125
179	1007 RISK OF RENAL TOXICITY WITH TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2010, 52, S388-S389.	3.7	5
180	Safety and efficacy of virmidine versus ribavirin in VISER2: Randomized, double-blind study in therapy-naïve hepatitis C patients. <i>Journal of Hepatology</i> , 2010, 52, 32-38.	3.7	43

#	ARTICLE	IF	CITATIONS
181	A multidisciplinary approach to the management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	8
182	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	0
183	Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 2 p preceding 4-15.	0.3	1
184	Editorial: To "Be" or Not to "Be" That Is the Question. <i>American Journal of Gastroenterology</i> , 2009, 104, 1948-1952.	0.4	18
185	A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2009, 3, 480-489.	4.2	22
186	The new epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , 2009, 8, 3-9.	0.3	0
187	Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 784-789.	2.0	18
188	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009, 29, 375-383.	3.9	8
189	W1811 HBV Screening in Asian Pacific Islander Americans: An Interim Analysis of the Hep B Free Program. <i>Gastroenterology</i> , 2009, 136, A-867.	1.3	0
190	W1816 HBV Management Among US Clinicians: Gaps in Clinical Competence and Practice Performance—Survey Findings. <i>Gastroenterology</i> , 2009, 136, A-868.	1.3	0
191	T1002 Clinical Epidemiology of Wilson Disease in Patients with Concurrent Liver Disease. <i>Gastroenterology</i> , 2009, 136, A-844.	1.3	0
192	Hepatitis B treatment: Current best practices, avoiding resistance. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S14-S19.	1.3	15
193	Monotherapy vs multiple-drug therapy: The experts debate. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, S20-S24.	1.3	2
194	The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. <i>Value in Health</i> , 2008, 11, 527-538.	0.3	118
195	Evaluating antiviral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1240-1252.	3.7	31
196	Diagnosis of Chronic Hepatitis B and the Implications of Viral Variants and Mutations. <i>American Journal of Medicine</i> , 2008, 121, i-OBC.	1.5	2
197	787 NEGATIVE TISSUE PCR DOES NOT CONFER REDUCED RISK OF RELAPSE AFTER TREATMENT OF HCV IN PATIENTS POST-LIVER TRANSPLANT. <i>Journal of Hepatology</i> , 2008, 48, S294.	3.7	0
198	W1012 Treatment of Hepatitis C Associated Severe Mixed Cryoglobulinemic Syndrome with Plasma Exchange Improves Tolerability and Response to Interferon-Based Therapy. <i>Gastroenterology</i> , 2008, 134, A-832.	1.3	0

#	ARTICLE	IF	CITATIONS
199	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008, 4, 19-33.	1.7	41
200	Hepatocellular carcinoma (HCC): current and evolving therapies. <i>IDrugs: the Investigational Drugs Journal</i> , 2008, 11, 198-203.	0.7	9
201	Medical therapies to extend survival in hepatocellular carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 1-14; quiz 15.	0.3	1
202	A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2007, 102, 2718-2723.	0.4	50
203	Customizing the Management of Chronic Hepatitis B Virus Infection. <i>Seminars in Liver Disease</i> , 2007, 27, 009-017.	3.6	8
204	Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nilotrexed or Doxorubicin. <i>Journal of Clinical Oncology</i> , 2007, 25, 3069-3075.	1.6	249
205	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007, 47, 51-59.	3.7	47
206	[563] PREDICTIVE VALUE FOR LOW LEVEL HEPATIC FIBROSIS IN CHRONIC HEPATITIS C (CMC) PATIENTS: COMPARISON OF FIVE NON-INVASIVE INDICES. <i>Journal of Hepatology</i> , 2007, 46, S214.	3.7	2
207	Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S67-S78.	3.4	5
208	Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. <i>Pharmacoeconomics</i> , 2007, 25, 963-977.	3.3	42
209	Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant to Standard Immunosuppressive Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 799-802.	4.4	82
210	Genotyping and Genomic Sequencing in Clinical Practice. <i>Clinics in Liver Disease</i> , 2007, 11, 761-795.	2.1	15
211	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	1.3	324
212	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon- β 1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007, 45, 569-578.	7.3	108
213	Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 324-329.	7.3	177
214	Do we need to MEND the MELD?. <i>Liver Transplantation</i> , 2007, 13, 486-487.	2.4	11
215	Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C. <i>Liver International</i> , 2007, 27, 1111-1118.	3.9	11
216	Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. <i>Liver International</i> , 2007, 27, 1394-1401.	3.9	78

#	ARTICLE	IF	CITATIONS
217	Improving outcomes for patients with chronic hepatitis B. <i>Current Gastroenterology Reports</i> , 2007, 9, 14-22.	2.5	22
218	Improving clinical trial design for hepatocellular carcinoma treatments. <i>Oncology Reviews</i> , 2007, 1, 45-52.	1.8	1
219	Hepatocellular Carcinoma: Overcoming Challenges in Disease Management. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 252-261.	4.4	57
220	Chronic Hepatitis B: Current Testing Strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 666-676.	4.4	70
221	Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 233-248.	4.4	43
222	Entecavir. <i>Drugs</i> , 2006, 66, 1623-1624.	10.9	0
223	Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , 2006, 44, 915-924.	7.3	278
224	Hepatitis B in liver transplant recipients. <i>Liver Transplantation</i> , 2006, 12, S54-S64.	2.4	19
225	Model for end-stage liver disease (MELD) exception guidelines. <i>Liver Transplantation</i> , 2006, 12, S85-S87.	2.4	63
226	Model for end-stage liver disease (MELD) exception for familial amyloidotic polyneuropathy. <i>Liver Transplantation</i> , 2006, 12, S100-S101.	2.4	5
227	Model for end-stage liver disease (MELD) exception for ascites. <i>Liver Transplantation</i> , 2006, 12, S88-S90.	2.4	9
228	Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome. <i>Liver Transplantation</i> , 2006, 12, S93-S94.	2.4	12
229	Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. <i>Liver Transplantation</i> , 2006, 12, S95-S97.	2.4	82
230	Model for end-stage liver disease (MELD) exception for bacterial cholangitis. <i>Liver Transplantation</i> , 2006, 12, S91-S92.	2.4	24
231	Model for end-stage liver disease (MELD) exception for cystic fibrosis. <i>Liver Transplantation</i> , 2006, 12, S98-S99.	2.4	13
232	Model for end-stage liver disease (MELD) exception for hepatic encephalopathy. <i>Liver Transplantation</i> , 2006, 12, S102-S104.	2.4	17
233	Model for end-stage liver disease (MELD) exception for portal hypertensive gastrointestinal bleeding. <i>Liver Transplantation</i> , 2006, 12, S112-S113.	2.4	8
234	Model for end-stage liver disease (MELD) exception for uncommon hepatic tumors. <i>Liver Transplantation</i> , 2006, 12, S122-S123.	2.4	7

#	ARTICLE	IF	CITATIONS
235	Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transplantation, 2006, 12, S105-S107.	2.4	86
236	Model for end-stage liver disease (MELD) exception for primary hyperoxaluria. Liver Transplantation, 2006, 12, S117-S118.	2.4	9
237	Model for end-stage liver disease (MELD) exception for unusual metabolic liver diseases. Liver Transplantation, 2006, 12, S124-S127.	2.4	7
238	Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transplantation, 2006, 12, S110-S111.	2.4	52
239	Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transplantation, 2006, 12, S114-S116.	2.4	76
240	Model for end-stage liver disease (MELD) exception for severe pruritus. Liver Transplantation, 2006, 12, S119-S119.	2.4	6
241	Model for end-stage liver disease (MELD) exception small-for-size syndrome. Liver Transplantation, 2006, 12, S120-S121.	2.4	7
242	Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. Liver Transplantation, 2006, 12, S108-S109.	2.4	18
243	Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transplantation, 2006, 12, S128-S136.	2.4	167
244	Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. Journal of Medical Virology, 2006, 78, 1296-1303.	5.0	56
245	T1653 Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. Clinical Infectious Diseases, 2006, 42, 1-7.	5.8	73
246	Treating HCV with ribavirin analogues and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 2006, 58, 488-488.	3.0	1
247	Treating HCV with ribavirin analogues and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 2006, 57, 8-13.	3.0	88
248	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2006, 354, 1001-1010.	27.0	1,345
249	Risk Factors and Treatment for Hepatocellular Carcinoma. Gastroenterology and Hepatology, 2006, 2, 477-478.	0.1	1
250	Current developments in the treatment of hepatitis and hepatobiliary disease. Clinical Advances in Hematology and Oncology, 2006, 4, 511-2.	0.3	0
251	Future Therapies for Hepatitis C. Antiviral Therapy, 2006, 11, 397-408.	1.0	28
252	Ascending Multiple Dose Pharmacokinetics of Viramidine, a Prodrug of Ribavirin, in Adult Subjects With Compensated Hepatitis C Infection. Journal of Clinical Pharmacology, 2005, 45, 275-285.	2.0	14

#	ARTICLE	IF	CITATIONS
253	Letter to the editors. Liver Transplantation, 2005, 11, 366-366.	2.4	4
254	Clinical Trial Results of New Therapies for HBV: Implications for Treatment Guidelines. Seminars in Liver Disease, 2005, 25, 29-39.	3.6	26
255	Management of hepatitis C virus in special populations: Patient and treatment considerations. Clinical Gastroenterology and Hepatology, 2005, 3, 311-318.	4.4	31
256	Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection. Clinics in Liver Disease, 2005, 9, 541-565.	2.1	24
257	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. Gastroenterology, 2005, 129, 494-503.	1.3	121
258	Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. Journal of Infectious Diseases, 2005, 191, 825-829.	4.0	225
259	Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. Journal of Hepatology, 2005, 43, 60-66.	3.7	100
260	Survival After Liver Transplantation in Patients With Hepatic Iron Overload: The National Hemochromatosis Transplant Registry. Gastroenterology, 2005, 129, 494-503.	1.3	78
261	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. Gastroenterology, 2005, 129, 1198-1209.	1.3	247
262	Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. World Journal of Gastroenterology, 2005, 11, 6295.	3.3	29
263	Hepatitis B in Liver Transplant Recipients as a Special Model of Antiviral Drug Development. , 2004, 96, 319-342.		0
264	Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. Journal of General Virology, 2004, 85, 811-820.	2.9	135
265	Studying the Treatment of Chronic Hepatitis B Viral Infection in Special Populations. , 2004, 96, 465-498.		1
266	A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	7.3	139
267	Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. Journal of Medical Virology, 2004, 73, 516-521.	5.0	64
268	Treating hepatitis C: the state of the art. Gastroenterology Clinics of North America, 2004, 33, 1-9.	2.2	10
269	Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects. Gastroenterology Clinics of North America, 2004, 33, xxiii-xxiv.	2.2	1
270	Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology, 2004, 127, 485-492.	1.3	447

#	ARTICLE	IF	CITATIONS
271	A model to predict severe HCV-related disease following liver transplantation. <i>Hepatology</i> , 2003, 38, 34-41.	7.3	190
272	De Novo Non-Alcoholic Fatty Liver Disease Following Orthotopic Liver Transplantation. <i>American Journal of Transplantation</i> , 2003, 3, 1413-1417.	4.7	30
273	Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. <i>Journal of Virological Methods</i> , 2003, 110, 29-35.	2.1	44
274	Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil 1 Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438.. <i>Gastroenterology</i> , 2003, 125, 107-116.	1.3	221
275	Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, 925-932.	1.3	202
276	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.4	165
277	Rate of natural disease progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 307-314.	3.7	80
278	Epidemiological and clinical differences between hepatitis B virus genotype B with and without recombination with genotype C. <i>Gastroenterology</i> , 2003, 124, A761-A762.	1.3	0
279	Elevated Expression of Tyrosine Kinase DDR2 in Primary Biliary Cirrhosis. <i>Autoimmunity</i> , 2002, 35, 521-529.	2.6	20
280	Characteristics of Hepatitis B Virus Isolates of Genotype G and Their Phylogenetic Differences from the Other Six Genotypes (A through F). <i>Journal of Virology</i> , 2002, 76, 6131-6137.	3.4	116
281	Potential reduction of post-transplantation HCV-related disease progression by a better selection of the donor. <i>Journal of Hepatology</i> , 2002, 36, 175-176.	3.7	0
282	Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 339-344.	2.8	5
283	Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. <i>Hepatology</i> , 2002, 35, 922-929.	7.3	114
284	A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. <i>Hepatology</i> , 2002, 36, 1253-1258.	7.3	91
285	Keratin 8 mutations in patient with cryptogenic liver disease. <i>Gastroenterology</i> , 2001, 120, A45.	1.3	0
286	Failure to identify specific sequence variations in genotype 1b HCV NS58 associated with response to interferon/ribavirin therapy. <i>Gastroenterology</i> , 2001, 120, A367.	1.3	1
287	AUTOIMMUNE LIVER DISEASE. <i>Clinics in Liver Disease</i> , 2001, 5, 287-314.	2.1	30
288	A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2001, 33, 424-432.	7.3	389

#	ARTICLE	IF	CITATIONS
289	Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 581-587.	2.4	86
290	Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. <i>Journal of Virological Methods</i> , 2001, 98, 153-159.	2.1	76
291	Keratin 8 Mutations in Patients with Cryptogenic Liver Disease. <i>New England Journal of Medicine</i> , 2001, 344, 1580-1587.	27.0	163
292	Chemo-embolization for treatment of hepatocellular carcinoma discovered while awaiting liver transplantation: A two-center experience. <i>Gastroenterology</i> , 2000, 118, A1010-A1011.	1.3	0
293	"Delayed" HCV RNA clearance on rebetron therapy: A comparison of week 12 responders VS. late responders. <i>Gastroenterology</i> , 2000, 118, A947.	1.3	0
294	Hepatitis C and hepatocellular carcinoma in African Americans. <i>Gastroenterology</i> , 2000, 118, A1435.	1.3	1
295	Future Directions in the Treatment of Patients with Chronic Hepatitis C Virus Infection. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999, 13, 57-62.	1.7	8
296	Treatment of chronic hepatitis B: New antiviral therapies. <i>Current Gastroenterology Reports</i> , 1999, 1, 20-26.	2.5	7
297	Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. <i>Hepatology</i> , 1999, 29, 1581-1586.	7.3	281
298	Fetal microchimerism alone does not contribute to the induction of primary biliary cirrhosis. <i>Hepatology</i> , 1999, 30, 833-838.	7.3	111
299	Long-term follow-up after liver transplantation in patients with hepatic iron overload. <i>Liver Transplantation</i> , 1999, 5, 369-374.	1.8	47
300	Are infectious agents involved in primary biliary cirrhosis? A PCR approach. <i>Journal of Hepatology</i> , 1999, 31, 664-671.	3.7	84
301	Is there a serological difference between men and women with primary biliary cirrhosis?. <i>American Journal of Gastroenterology</i> , 1999, 94, 2482-2486.	0.4	4
302	GB Virus C (GBV-C/HGV) and E2 Antibodies in Children Pre-liver and Post-liver Transplant. <i>Pediatric Research</i> , 1999, 45, 795-798.	2.3	8
303	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998, 27, 213-222.	7.3	324
304	MINIMAL CRITERIA FOR PLACEMENT OF ADULTS ON THE LIVER TRANSPLANT WAITING LIST. <i>Transplantation</i> , 1998, 66, 956-962.	1.0	84
305	Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein. <i>Journal of Virology</i> , 1998, 72, 2738-2744.	3.4	68
306	Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. <i>Hepatology</i> , 1996, 24, 6-9.	7.3	270

#	ARTICLE	IF	CITATIONS
307	Transmission of hepatitis B virus through allotransplantation. Liver Transplantation, 1996, 2, 161-164.	1.8	8
308	Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. Digestive Diseases and Sciences, 1995, 40, 2595-2601.	2.3	18
309	Recent developments in the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs, 1995, 4, 95-115.	4.1	5
310	Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. Journal of Hepatology, 1995, 22, 257-262.	3.7	32
311	Optimization for the detection of hepatitis C virus antigens in the liver. Journal of Hepatology, 1994, 20, 143-147.	3.7	56
312	Variation in Antibody Reactivity to the Hepatitis C Virus by Comparative Immunoscreening and Enzyme Immunoassay. Viral Immunology, 1993, 6, 49-54.	1.3	0
313	A review of liver transplantation for the dentist and guidelines for dental management. Special Care in Dentistry, 1993, 13, 74-80.	0.8	15
314	Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.. Journal of Clinical Investigation, 1991, 88, 270-281.	8.2	302
315	Calcium compartmentation and exchange rates in primary hepatocyte culture. Analytical Biochemistry, 1990, 187, 187-196.	2.4	3
316	Chronic Hepatitis B Viral Infection. , 0, , 2112-2138.		1
317	Entecavir versus other oral antiviral drugs for chronic hepatitis B. The Cochrane Library, 0, , .	2.8	0
318	Chronic Hepatitis B Viral Infection. , 0, , 636-641.		0